Johnson & Johnson Global Neurovascular Business President Mark Dickinson Announces Departure from the World's Second-Largest Medical Device Company, Concluding a 26-Year Career at Johnson & Johnson.

In recent years, Johnson & Johnson's cardiovascular and cerebrovascular business has undergone tremendous changes. To strengthen its cardiovascular and cerebrovascular portfolio, Johnson & Johnson has spent over $300 billion on several major acquisitions. While introducing new businesses, it also faces the decline of older ones. For instance, its electrophysiology and neurointervention businesses are encountering fierce competition from strong market rivals, leading to rapidly increasing future uncertainties.

Therefore, the market also hopes that Johnson & Johnson will make adjustments and sell some businesses with unclear prospects. For exampleThe neurovascular business was rumored to be up for sale at the beginning of the year. Although Johnson & Johnson did not officially respond, the market still believes that Johnson & Johnson will sell the business.

Therefore, recentlySignificant changes have occurred in the leadership of the neurointervention business. First,Michael Bodner has been appointed asNew Electrophysiology and Neurovascular Business GroupChairman Ren. SubsequentlyFormer President of Neurovascular BusinessMark Dickinson Announces Departure. This change implies Johnson & Johnson executives forThe current situation of electrophysiology and neurovascular business is extremely unsatisfactory, hoping for new appointments.The chairman can leadElectrophysiology and neurovascular businesses have emerged from困境, returning to the right track. After allElectrophysiology and neurovascular businesses are the foundation of Johnson & Johnson's cardiovascular and cerebrovascular operations; an unstable foundation could easily render Johnson & Johnson's years of effort futile.

Mark Dickinson's Farewell Speech

"Starting from joining the Ethicon division in the UK, to participating in building an excellent electrophysiology business, and then serving as the global president leading the neurovascular team for the past six years, every year has offered invaluable opportunities for learning and growth while working alongside outstanding talents. I am deeply proud of what we have collectively achieved. Reflecting on my time at Johnson & Johnson, I fully recognize that the colleagues I have had the privilege to work with have not only shaped my professional journey but also profoundly influenced my growth as a leader. From each colleague, I have drawn inspiration—your dedication, innovative thinking, and resilience continually motivate me. At the same time, I have taken it upon myself to nurture talent and build an inclusive and driven team culture. Witnessing the growth and success of team members has been the most precious reward of my career. Without the support of exceptional talent, we could achieve nothing. Thank you for the wonderful memories and cherished friendships, which I will always treasure." He concluded by saying, "Let us embrace the new future together!"